CD47 Promotes Age-Associated Deterioration in Angiogenesis, Blood Flow and Glucose Homeostasis
Authors:
- Kedar GhimireKedar Ghimire
- Yao LiYLYao Li
- Takuto ChibaTCTakuto Chiba
- Sohel M. JuloviSohel M. Julovi
- Jennifer LiJLJennifer Li
- Mark A. RossMRMark A. Ross
- Adam C. StraubAdam C. Straub
- Philip J. O’connellPOPhilip J. O’connell
- Curzio RüeggCurzio Rüegg
- Patrick J. PaganoPPPatrick J. Pagano
- Jeffrey S. IsenbergJIJeffrey S. Isenberg
- Natasha M. RogersNatasha M. Rogers
Open Access
Abstract
The aged population is currently at its highest level in human history and is expected to increase further in the coming years. In humans, aging is accompanied by impaired angiogenesis, diminished blood flow and altered metabolism, among others. A cellular mechanism that impinges upon these manifestations of aging can be a suitable target for therapeutic intervention. Here we identify cell surface receptor CD47 as a novel age-sensitive driver of vascular and metabolic dysfunction. With the natural aging process, CD47 and its ligand thrombospondin-1 were increased, concurrent with a reduction of self-renewal transcription factors OCT4, SOX2, KLF4 and cMYC (OSKM) in arteries from aged wild-type mice and older human subjects compared to younger controls. These perturbations were prevented in arteries from aged CD47-null mice. Arterial endothelial cells isolated from aged wild-type mice displayed cellular exhaustion with decreased proliferation, migration and tube formation compared to cells from aged CD47-null mice. CD47 suppressed ex vivo sprouting, in vivo angiogenesis and skeletal muscle blood flow in aged wild-type mice. Treatment of arteries from older humans with a CD47 blocking antibody mitigated the age-related deterioration in angiogenesis. Finally, aged CD47-null mice were resistant to age- and diet-associated weight gain, glucose intolerance and insulin desensitization. These results indicate that the CD47-mediated signaling maladapts during aging to broadly impair endothelial self-renewal, angiogenesis, perfusion and glucose homeostasis. Our findings provide a strong rationale for therapeutically targeting CD47 to minimize these dysfunctions during aging.Keywords
Funding Information
- National Institutes of Health (R01 HL-108954 to JSI, 1R01HL112914-01A1 to JSI, 1R21EB017184-01A1 to JSI)
- National Health and Medical Research Council (GNT1138372 to NMR, GNT1156977 to NMR)
- Diabetes Australia (General Grant (2018) to NMR and KG)
This publication has 61 references indexed in Scilit:
- Thrombospondin-1 Signaling through CD47 Inhibits Self-renewal by Regulating c-Myc and Other Stem Cell Transcription FactorsScientific Reports, 2013
- Thrombospondin-1 Inhibits VEGF Receptor-2 Signaling by Disrupting Its Association with CD47Journal of Biological Chemistry, 2010
- Low concentrations of nitric oxide delay the differentiation of embryonic stem cells and promote their survivalCell Death & Disease, 2010
- Thrombospondin-1 supports blood pressure by limiting eNOS activation and endothelial-dependent vasorelaxationCardiovascular Research, 2010
- Neural mechanisms of ageing and cognitive declineNature, 2010
- Akt and c-Myc Differentially Activate Cellular Metabolic Programs and Prime Cells to Bioenergetic InhibitionJournal of Biological Chemistry, 2010
- Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapiesNature Reviews Cancer, 2009
- miR-126 Regulates Angiogenic Signaling and Vascular IntegrityDevelopmental Cell, 2008
- Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined FactorsCell, 2007
- In vitro assays of angiogenesis for assessment of angiogenic and anti-angiogenic agentsMicrovascular Research, 2007